Life Science Nation Newsletter  |  December 31, 2015  |  Issue 144

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Dec. 24 - Dec. 30)
Searches For Clinical-Stage Life Science Opportunities
Focuses On Neurodegeneration & Psychology Drugs
Seeks Minimally Invasive Devices, Diagnostics & Robotics
Seeks Seed, Spin-Out and Late Stage Life Science Opportunities
In This Issue
LSN Videos
RESI Boston 2015 Investors Panel

Video Recap of RESI@TMCx 2015

Licensing Deals in Year 2015: Early Stage Endocrine Assets Scored Big 
By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN,

Year 2015 has been buzzing with biopharma licensing deals. Compared to previous years, large pharmaceutical companies have become more aggressive in pursuing early stage assets to replenish their pipelines. Against the backdrop of headline-grabbing mega deals, we have dug into the LSN Licensing Deals Platform to examine the key data points that can tell us about the overall deal-making activity for year 2015.  (LSN's data covers licensing deals, but not M&A activity)...

Highlights of 2015: Next Phase's Top 10 Articles 
By Lucy Parkinson, Director of Research, LSN,
Nono Hu, Director of Marketing, LSN

We've covered many topics in life science fundraising over the last year, and here's a roundup of the articles that won the most reader appeal. The list includes some retrospectives and look-aheads, some deep dives on working with a pharma company or with a philanthropic fund, and some tactical tips on how to meet an investor and build a productive relationship. We hope you'll enjoy taking a second look at these 2015 highlights. 
  • Year-End Roundup: Pharma Licensing Deals
  • 11 Tips for Creating a Successful Pitch Deck
  • Formulating the Introductory Email to Potential Investors
  • CRO Trends in 2015
  • How to Write a Compelling Partnering Message
  • The Life Science Venture Philanthropy Landscape
  • Getting the Most from a 30-Minute Investor Meeting
  • How Do Investors Assess a Management Team?
  • Family Offices: The New VCs
  • Pitching to a Foundation? Be Prepared for These Issues
Redefining Early Stage Investments (RESI) Conference: Biotech Family Office Panel
By Cole Bunn, Research Analyst, LSN

Family offices are an investor class that has recently garnered a lot of attention from life science entrepreneurs. Their wide variety of motivations and transaction types and generally speaking, more flexible term sheets, make these investors a great partner for biotech companies undertaking the daunting task of commercializing therapeutic products.

At RESI San Francisco, the Biotech Family Office Panel will provide insights into each represented firm's current interests and outlook on the biotech sector, how they source and evaluate deals and their position in the investment ecosystem.

Moderated by Lisa Rhoads, Managing Director, Easton Capital, this panel will feature: 
  • Jim Mellon, Chairman & Founder, Mann Bioinvest
  • Rick Jones, Director, Broadview Ventures
  • Jayson Rieger, SVP of Business Development, PBM Capital Group
  • Christine de los Reyes, Vice President, Alopexx Enterprises